BioXcel Therapeutics (BTAI) Cash from Operations (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Cash from Operations of 11809000.0 for Q1 2026, up 1.94% year-over-year from 11583920.09 in Q1 2025, and up 16.9% quarter-over-quarter from 14210000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Cash from Operations (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Cash from Operations history runs 10 years deep, the most recent figure standing at 11809000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 1.94% year-over-year to 11809000.0; the TTM figure through Mar 2026 stood at 57381000.0 (up 13.54% YoY), while the FY2025 annual figure was 57615000.0, up 20.01% from the prior year.
- Cash from Operations for Q1 2026 stood at 11809000.0, up from 14210000.0 in the prior quarter.
- The five-year high for Cash from Operations was 11809000.0 in Q1 2026, with the low at 52353000.0 in Q1 2023.
- The 5-year median for Cash from Operations is 23174000.0 (2024), against an average of 25399882.35.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations plunged 93.85% in 2022, then soared 66.18% in 2024.
- BioXcel Therapeutics' Cash from Operations stood at 38639000.0 in 2022, then surged by 30.48% to 26863000.0 in 2023, then surged by 44.87% to 14809000.0 in 2024, then gained by 4.04% to 14210000.0 in 2025, then rose by 16.9% to 11809000.0 in 2026.
- Business Quant data shows BTAI's Cash from Operations at 11809000.0 in Q1 2026, 14210000.0 in Q4 2025, and 18787000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.46 Mn | 24.46 Mn | 160,000.00 | -6.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.10 Mn |
| Jun 30, 2026 | -6.10 Mn |
| Mar 31, 2026 | -11.81 Mn |
| Mar 31, 2026 | -11.81 Mn |
| Dec 31, 2025 | -14.21 Mn |
| Dec 31, 2025 | -14.21 Mn |
| Sep 30, 2025 | -18.79 Mn |
| Sep 30, 2025 | -18.79 Mn |
| Jun 30, 2025 | -12.58 Mn |
| Jun 30, 2025 | -12.58 Mn |
| Mar 31, 2025 | -12.04 Mn |
| Mar 31, 2025 | -12.04 Mn |
| Dec 31, 2024 | -14.81 Mn |
| Dec 31, 2024 | -14.81 Mn |
| Sep 30, 2024 | -16.34 Mn |
| Sep 30, 2024 | -16.34 Mn |
| Jun 30, 2024 | -23.17 Mn |
| Jun 30, 2024 | -23.17 Mn |
| Mar 31, 2024 | -17.71 Mn |
| Mar 31, 2024 | -17.71 Mn |